News & Analysis as of

Sanofi-Aventis Biosimilars

Goodwin

FDA Approves First Rapid-Acting Insulin Biosimilar Product for the Treatment of Diabetes

Goodwin on

On February 14, 2025, the U.S. Food and Drug Administration (“FDA”) approved Sanofi-Aventis U.S. LLC’s (“Sanofi”) MERILOG™ (insulin-aspart-szjj), a biosimilar to Novo Nordisk A/S’s (“Novo Nordisk”) NOVOLOG® (insulin aspart),...more

Goodwin

Updates on Rituximab Proposed Biosimilars

Goodwin on

The past few days have seen a lot of activity on the rituximab biosimilar front. ..According to a joint press release, Sanofi and JHL Biotech, a biopharmaceutical company based in China, formed an alliance to collaborate...more

Goodwin

Sanofi Sues Merck Over Proposed Insulin Glargine Biosimilar

Goodwin on

Last week, Sanofi-Aventis U.S. LLC filed a complaint against Merck Sharp & Dohme Corp. over its proposed biosimilar to Lantus (insulin glargine injection). The complaint asserts that Merck will infringe 10 different U.S....more

3 Results
 / 
View per page
Page: of 1

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
- hide
- hide